Robert Suriano
Overview
Explore the profile of Robert Suriano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeSouza N, Nielsen K, Jarboe T, Carnazza M, Quaranto D, Kopec K, et al.
Biomolecules
. 2024 Apr;
14(4).
PMID: 38672402
Circular RNAs (circRNAs) are stable, enclosed, non-coding RNA molecules with dynamic regulatory propensity. Their biogenesis involves a back-splicing process, forming a highly stable and operational RNA molecule. Dysregulated circRNA expression...
2.
Reyes I, Reyes N, Suriano R, Iacob C, Suslina N, Policastro A, et al.
Cancer Biomark
. 2019 Jan;
24(1):71-83.
PMID: 30614796
Background: Thyroid cancer is the most common endocrine malignancy worldwide, with the predominant form papillary thyroid carcinoma (PTC) representing approximately 80% of cases. Objective: This study was addressed to identify...
3.
Maniyar R, Chakraborty S, Suriano R
J Cancer
. 2018 Nov;
9(21):3874-3885.
PMID: 30410590
Angiogenesis, a highly regulated process, is exploited by tumors like breast cancer to ensure a constant supply of oxygen and nutrients and is key for tumor survival and progression. Estrogen...
4.
Hanly E, Tuli N, Bednarczyk R, Suriano R, Geliebter J, Moscatello A, et al.
Oncotarget
. 2016 Jan;
7(8):8676-87.
PMID: 26735176
Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a...
5.
George A, Suriano R, Rajoria S, Osso M, Tuli N, Hanly E, et al.
J Cancer
. 2015 Dec;
6(12):1320-30.
PMID: 26640592
Over expression of various immunogenic melanoma associated antigens (MAAs) has been exploited in the development of immunotherapeutic melanoma vaccines. Expression of MAAs such as MART-1 and gp100 is modulated by...
6.
Hanly E, Rajoria S, Darzynkiewicz Z, Zhao H, Suriano R, Tuli N, et al.
BMC Res Notes
. 2014 Mar;
7:187.
PMID: 24673746
Background: Thyroid cancer is the most common endocrine-related cancer in the United States and its incidence is rising rapidly. Since among various genetic lesions identified in thyroid cancer, the BRAFV600E...
7.
Suriano R, Rajoria S, George A, Geliebter J, Tiwari R, Wallack M
Mol Clin Oncol
. 2014 Mar;
1(3):466-472.
PMID: 24649193
Development of a melanoma-specific vaccine is of clinical necessity. Therefore, a phase III, randomized, double-blind trial was performed (June 1988-June 1991) to assess the clinical effectiveness of our vaccinia melanoma...
8.
Suriano R, Rajoria S, George A, Geliebter J, Wallack M, Tiwari R
J Cancer
. 2013 Jul;
4(5):371-82.
PMID: 23833682
Transformation of the pigment producing melanocytes into melanoma is a complex multi-step process involving the enhanced expression of various antigens considered as immunotherapeutic targets. Significant progress in melanoma research has...
9.
George A, Rajoria S, Suriano R, Mittleman A, Tiwari R
Mol Cancer
. 2012 Oct;
11:80.
PMID: 23088607
Background: Rapid breast tumor development relies on formation of new vasculature to supply the growing malignancy with oxygenated blood. Previously we found that estrogen aided in this neovasculogenesis via recruitment...
10.
Rajoria S, Suriano R, Wilson Y, George A, Geliebter J, Schantz S, et al.
Oncol Lett
. 2012 Aug;
2(3):453-457.
PMID: 22866102
Neo-vascularization is essential for tumor growth and metastasis and is presumably initiated by bone marrow-derived endothelial progenitor cells (BM-EPCs). These cells predominantly reside in the bone marrow and are recruited...